PATIENT ALERT: If you have tested positive for COVID in the last 14 days, please notify us and reschedule your appointment. Online COVID pre-screening is REQUIRED 72 hours prior to your appointment. Please CLICK HERE to complete the questionnaire.  Masks are still required in all offices.   Information regarding COVID-19.  

Clinical Research & Trials

USO 19226

A Phase Iii Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating The Efficacy And Safety Of Gdc-9545 Combined With Palbociclib Compared With Letrozole Combined With Palbociclib In Patients With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer (Bo41843)

 

Disease Types: Breast Cancer Research

Eligibility Requirements:

-ER (+), HER2 (-) locally advanced or metastatic breast cancer with measurable disease 
-No history of systemic therapy in the locally advanced or metastatic setting
-No recurrence during or within 12 months of neoadjuvant or adjuvant treatment with AI or CDK 4/6 inhibitor
-No prior treatment with fulvestrant (SERD)
-No history of clinically significant cardiac disease, HIV, or GI disease that effects absorption 

Available at: